Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials
Signal Transduction and Targeted Therapy (2021) - Comments
pubmed: 34267185  doi: 10.1038/s41392-021-00692-3  issn: 2059-3635 

Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo, Jia-Lu Zhang, Bo-Pei Cui, Zhi-Ming Wu, Ming-Wei Wei, Zhi-Long Ma, Hai-Lin Peng, Hong-Xing Pan, Lin Fan, Jing Zhang, Jiu-Qin Wan, Zhong-Kui Zhu, Xue-Wen Wang, Feng-Cai Zhu